More and more new products are “developed in Shanghai”

When people think of R&D, they picture white coats and all kinds of reagents. Yet Sanofi’s translational medicine research center sits in an office building in Jing’an. Step inside and researchers are busy at their computers, designing clinical trial protocols, analysing data and communicating with doctors and regulators. Laboratory testing is outsourced to specialised institutions.

 
There are no laboratory benches, yet the center cannot do without hospitals for a single moment. “I have lost count of how many times I have been to Huashan Hospital this year,” said Tang Lei, head of translational medicine at Sanofi China. Visiting experts, discussing protocols and reviewing raw data are part of her daily work.

When people think of R&D, they picture white coats and all kinds of reagents. Yet Sanofi’s translational medicine research center sits in an office building in Jing’an. Step inside and researchers are busy at their computers, designing clinical trial protocols, analysing data and communicating with doctors and regulators. Laboratory testing is outsourced to specialised institutions.

 
There are no laboratory benches, yet the center cannot do without hospitals for a single moment. “I have lost count of how many times I have been to Huashan Hospital this year,” said Tang Lei, head of translational medicine at Sanofi China. Visiting experts, discussing protocols and reviewing raw data are part of her daily work.
 
In September this year, the newly upgraded Sanofi Shanghai Foreign-Invested R&D Innovation Center was inaugurated in Jing’an, with a separate legal entity for R&D; the Center of Excellence in Translational Medicine that the company has built with Huashan Hospital is its fourth worldwide and its first outside Europe.
 
This is no isolated case. Regional headquarters strengthening their R&D functions has become a trend. At the same time, the most decisive parts of R&D — framing the questions, designing the protocols, organising resources — are concentrating at headquarters. Which trials to run, which products to develop, how many people and how much money to invest are increasingly decided in Shanghai.

 

“Writing the script” becomes Shanghai’s task

In the past, the Shanghai team was mostly handed a “script” already written globally.

Sanofi and Huashan Hospital have worked together for many years, previously focusing mainly on later-stage international multicentre clinical trials. Tang Lei explained that in such trials Chinese enrollees usually account for only about 15% of patients, the protocol is designed by the global team, and the Chinese team is mainly responsible for execution.

Today, two early-stage clinical trials under the collaboration will be conducted entirely in China, with all participants recruited in China. The Shanghai team takes part in protocol design from the outset, so that trials fit the real conditions of domestic hospitals and fully take into account patients’ existing standard treatments.

Why entrust the “script-writing” task to Shanghai? The first reason is time. Patents on innovative drugs offer limited protection, and time saved at each stage can add up to shorten by one year a development cycle that usually takes ten.

Not long ago, the global team visited the Phase I clinical trial center at Huashan Hospital, and one detail stunned them: it has no fewer than 42 beds. Some smaller centers in Europe have only a few or a dozen beds. That means that for a small-scale trial, all the participants needed can be admitted on the same day — an undoubted advantage.

What underpins this shift of tasks upstream is Shanghai’s dense professional network. Reviewing its list, Sanofi found that about 90% of its partner testing institutions are located in Shanghai, with the rest in nearby cities such as Ningbo and Suzhou. Together with more than 200 R&D colleagues in the city and accumulated capabilities in data science and real-world research, this led Sanofi to concentrate the researchers of its translational medicine team in Jing’an.

Multinationals have found that when R&D becomes “lighter” it actually becomes more “demanding” about cities: it needs hospitals, specialised institutions and talent clustered densely within a small area. Shanghai’s rich resources form the nodes of an innovation network, providing favourable conditions for taking on more important R&D tasks — and creating a new opportunity for central urban districts to develop R&D functions.

The newly established Center of Excellence in Translational Medicine will further connect the research strengths of the company and the hospital. Around translational research, researchers from both sides can propose topics, which are then approved as projects after joint evaluation. Clinical observations can thus feed into the R&D process earlier.

Shi Wang, president of Sanofi Greater China, said the Shanghai R&D Innovation Center will become the company’s largest translational medicine research center in China, and the Chinese team is deeply involved in more than 90% of the group’s globally synchronised development projects. In future, the group plans to place about one third of its new projects in China.

This is not an isolated case. Of the world’s top 20 pharmaceutical companies and top 20 medical device companies, 19 of each have set up headquarters, manufacturing or R&D centers in Shanghai. Recently, Boehringer Ingelheim also announced a new R&D center in Zhangjiang to strengthen capabilities such as early clinical development.

Making “neighbouring resources” connect

Dermatologists at Huashan Hospital found that the hair-loss grading scale commonly used in clinical practice works well for moderate to severe cases but easily misses subtle early changes. Bai Lin, director of L’Oréal China’s R&D and Innovation Center, said many Chinese consumers already feel “hair-volume anxiety” and want early intervention before their hair loss reaches the medical diagnostic threshold.

Researchers from both sides combined clinical follow-up with L’Oréal’s rapid scalp and hair testing system, analysed high-resolution scalp images of 400 Chinese men, and produced a “seven-level microscopic hair-loss atlas”, hoping to establish a new assessment benchmark for early intervention.

At the very source of R&D, change is under way. In the past, when developing functional skincare products, clinicians sat downstream in R&D, verifying results and evaluating products; now they frame questions together with company researchers, interpret results, and feed clinical observations back to the laboratory.

Last November, L’Oréal China and Huashan Hospital set up a dermatological science laboratory co-created by clinicians and researchers. Doctors observed that during light-based acne treatment many patients still feel irritation and discomfort. L’Oréal’s R&D team therefore worked with a local biotech company to develop a new formula. In April this year the first result landed, with the global launch of La Roche-Posay’s supramolecular oil-control balancing lotion.

This year’s survey by the European Union Chamber of Commerce in China shows that among the factors benefiting R&D in China, local partners were chosen by 47% of respondent companies, second only to local talent and market size.

Yet concentrating resources in a single city does not mean collaboration happens automatically.

The first site designated for the joint laboratory is at Meichuang Jingjie, an ecosystem platform co-built by the government, medical research institutions and enterprises. A relevant official said multinationals are eager to connect with local agile innovation, while local companies lack clinical data, international aesthetic sensibility, compliance systems and global channels. Seen from a higher level, companies have R&D capability and market channels, and hospitals are not short of clinical findings, but neither side can easily find a product “exit” on its own.

Meichuang Jingjie plays the role of “interpreter” and “adhesive”, collecting needs, matching partners and tracking projects, so that the two sides move from “not understanding each other” to “making products on the same list”. At the same time it coordinates data sharing, intellectual property and the pace of productisation, and provides services such as efficacy testing and registration consulting. To date the platform has brought in more than 130 companies and works with over 20 institutions. The platform also admits, however, that IP negotiations for joint R&D take a long time and that clinical testing resources at top-tier hospitals remain tight — issues still to be explored.

Research suggests that foreign-invested R&D institutions in Shanghai account for less than 3% of the total number of local high-tech enterprises, yet they are a “keystone species” in Shanghai’s innovation ecosystem, with a significant influence on it. To help the “keystone species” play its role, the integration of foreign R&D institutions with the local innovation ecosystem must be accelerated. That is why finding “interfaces” for resource elements matters even more than clustering the resources themselves.

Since last year, Jing’an has also integrated the launch scenarios of Nanjing West Road, the Meichuang Jingjie platform, beauty headquarters and medical research resources, so that research results have the chance to run all the way along the path of product development, validation and market application.

In July this year, eight foreign-invested R&D innovation centers in Jing’an launched the Foreign-Invested Innovation Ecosystem Alliance; in September, L’Oréal China, together with Ruijin Hospital, Huashan Hospital, Shanghai Skin Disease Hospital and Meichuang Jingjie, launched the Beauty and Health Industry-Academia-Research-Medical Innovation Alliance. These measures move cooperation from isolated points to mechanisms.

At the level of capital, links are strengthening too. Sanofi and Cathay Capital set up a 2-billion-yuan pharmaceutical innovation fund last year, while L’Oréal China and partners established the Cathay Beauty Future Fund and the Beauty Pilot Fund. On the other side of the Huangpu River, open innovation platforms such as Johnson & Johnson JLABS@Shanghai and the Roche China Accelerator are also connecting start-up teams, using the technology, capital and platform resources of large companies to support early-stage innovation.

On this vibrant soil of Shanghai, multinationals are exploring different ways of organising innovation. But they share one thing: they draw the city’s rich resources into concrete projects and strive to turn them into corporate innovation capability.

Who defines the next new product

“Orders in China, decisions in Germany, supply worldwide.” That was the past business model of Pepperl+Fuchs, a German industrial automation company.

A battery manufacturing customer asked for a sensor that responds faster, is smaller and is compatible with industrial communication protocols. Under the old process, the request had to go to German headquarters for evaluation and improvement, and a round trip took several months.

Chinese customers cannot wait. Wang Kunlun, general manager of Pepperl+Fuchs China, said the life cycle of a global general-purpose product is usually measured in years, whereas Chinese customers demand rapid iteration; to meet their requirements, products also have to be redesigned for the Chinese supply chain. In the past the Chinese team could only handle selection, configuration and commissioning, and “could not influence product strategy”.

In July this year, Pepperl+Fuchs folded the sales and service entities of its two major businesses in China into its Greater China headquarters, concentrating functions such as finance, human resources and supply chain coordination in Shanghai. The battery customer’s project was reassigned to the Shanghai team for requirement gathering, application assessment and test commissioning, with commercial terms and delivery schedules approved locally; the project has now been delivered. With Jing’an’s support, Pepperl+Fuchs plans to open its Shanghai R&D center in the first quarter of next year, handing responsibilities such as the regional product roadmap, R&D budget and headcount, and product portfolio decisions to Shanghai.

“China is no longer just a market where we sell products; it is a market that ‘defines products’. R&D must be based in China and close to customers, which is why we chose a city like Shanghai with the densest talent pool and industrial ecosystem,” Wang Kunlun said.

Honeywell Technology’s approach is to put R&D directly in front of customers. The company has 11 R&D sites in China, each with its own specialty. To bring these dispersed professional strengths together, in September this year Honeywell Technology set up its China Innovation Institute in Pudong. When customers visit the institute they can not only talk directly with researchers but also connect at any time with R&D teams elsewhere. Shi Wei, chief technology officer for Greater China, said Shanghai is more like a “brain”.

Otis’s Shanghai Global R&D Center is the group’s largest R&D base in the world; the team moved into Qiantan, Pudong at the end of last year, joining the Greater China headquarters and the high-speed elevator center. Faced with China’s large-scale renewal of ageing elevators and the needs of an ageing population, the Shanghai team translated customer feedback into system solutions and technical standards, launching a third-generation smart elevator with designs including wider door openings and larger buttons.

Some scholars argue that the “technology gap” between multinationals and local Chinese companies is narrowing markedly. When a single global product can no longer win everywhere, the team that is closer to customers and adapts faster is better placed to define the product. PwC’s survey of multinational executives in China published this year also shows that 77% of respondents ranked competition as the primary factor driving localisation and restructuring.

A survey by the Jing’an District Commission of Commerce also confirms that among the district’s more than 150 multinational headquarters, companies with R&D functions perform better in revenue and tax growth. Jing’an has therefore made promoting the addition of R&D functions at multinationals a key lever.

But resources and authority do not arrive automatically. The survey of multinational executives in China shows that 73% of respondents consider headquarters or global cultural barriers and organisational resistance to be the biggest obstacle to localised innovation in China.

“Most of the teams we deal with are China or Asia-Pacific teams, but core decision-making authority sits abroad,” said the head of the Jing’an District Commission of Commerce. How to win R&D functions? The biggest competition does not come from other cities but from resource allocation inside the multinational group itself.

In March this year, Jing’an introduced “Jing’an Eight Measures”, the city’s first district-level policy dedicated to the transformation of foreign investment, as a lever to break the deadlock. At the same time, Jing’an seizes opportunities such as visits by global executives, headquarters matchmaking and professional services to acquaint multinational decision-makers with Shanghai’s advantages and support Shanghai teams in taking on more functions.

Since the start of this year, Jing’an has newly certified eight district-level foreign-invested R&D innovation centers. More multinationals are building or planning to upgrade R&D centers. Across the city, Shanghai has rolled out a series of policies encouraging foreign investment and the development of R&D centers. From January to August this year, the city certified 44 regional headquarters of multinationals and 39 foreign-invested R&D centers, bringing the cumulative totals to 1,120 and 675 respectively.

The comprehensive resource endowment of an economic hub city forms a powerful network supporting the upgrading of headquarters functions. Shanghai’s headquarters economy is moving from the initial clustering of institutions towards a clustering of R&D responsibilities, decision-making authority and resource-allocation capability.

As the place where questions are raised and decisions are made is increasingly chosen to be Shanghai, the city gains a greater say on the map of multinational corporations.


Source: Jiefang Daily

Author: Meng Qunshu

Editor: Shi